• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    PURPOSE: A composition containing levan as natural polysaccharides for simulating the growth of intestinal lactic acid-producing bacteria containing bifidus bacteria in the intestine by mixing microorganism-derived levan in powder or aqueous state with lactic acid bacteria. The composition remarkably increases the number of lactic acid in the intestine while reducing the pH of the lactic acid. CONSTITUTION: The composition for stimulating the growth of intestinal lactic acid-producing bacteria contains levan alone or a combination with lactic acid bacteria in a ratio of lactic acid bacteria to levan of 1:2 to 1:10. The composition contains 0.1 to 10% by weight of levan on a solid basis or 0.1 to 7% by weight of levan on a liquid basis. It prevents death of lactic acid bacteria with low acid resistance within the stomach to cause lactic acid bacteria in large quantities to reach the intestine and thus can be effectively used in health food and medicine.
    公开号:KR20030066902A
    申请号:KR1020020006644
    申请日:2002-02-06
    公开日:2003-08-14
    发明作者:장기효；강순아；김철호；이상기；하상도；이진국；편흥삼
    申请人:주식회사 코리즈；주식회사 고려한백 인터내셔널；주식회사 리얼바이오텍；
    IPC主号:
    专利说明:

    Composition including levan as growth stimulator for intestinal lactic acid-producing bacteria}
    [1] The present invention relates to an intestinal lactobacillus growth promoting composition comprising levan, and more particularly, by mixing leban derived from microorganisms with lactic acid bacteria in powder or aqueous solution to promote the growth of intestinal lactic acid bacteria including bifidus bacteria in the intestine. The present invention relates to an entero lactic acid bacteria growth promoting composition having excellent intestinal effects such as reducing and promoting the production of lactic acid and acetic acid.
    [2] Enterobacteriaceae inhabiting the human intestine include useful bacteria that protect the health of the host and harmful bacteria that adversely affect the health of the host, and the health condition is controlled by the balance of both. Intestinal soluble bacteria include bifidobacteria and lactobacilli, which are considered to play an important role in human health. However, harmful bacteria represented by Escherichia coli, food poisoning bacteria, staphylococci, etc. promote the decay of the intestine to cause aging, produce carcinogens, and are sensitive to the intestinal pH. That is, many harmful bacteria are greatly degraded under acidic conditions, and lactic acid bacteria have a strong survival rate even under relatively acidic conditions. Lactobacillus is a bacterium that produces a lot of lactic acid using carbohydrates, but breaks down proteins, but does not decay and does not produce harmful substances to the human body. Lactic acid includes that Bifidobacterium (Bifidobacterium), Lactobacillus (Lactobacillus), Streptococcus (Streptococcus) species, to produce the physiological activity of the first organic acid of such lactic acid bacteria by lowering the pH of the intestine to inhibit the growth of harmful bacteria Helps balance the gut flora Second, it produces beta-galactosidase (β-galactosidase) and works in favor of people with lactose dyspepsia. Third, lactic acid and acetic acid, fermentation products, exhibit anticancer activity that inhibits the growth of decaying bacteria and inhibits the production of carcinogens such as N-nitroso compounds and phenolic products. In addition, it exhibits an effect of inhibiting cholesterol synthesis, promoting vitamin synthesis, and inhibiting diarrhea-causing bacteria.
    [3] As a method for maintaining such intestinal lactic acid bacteria, particularly bifidus bacteria as enterobacteriaceae, two methods have been tried. Firstly, the method of orally administering the bifidus bacteria, and secondly, the method of orally administering the material, which is selectively used to the bifidus bacteria, namely, the bifidus factor, ultimately induces the proliferation of lactic acid bacteria. The characteristics of the factors that proliferate known lactic acid bacteria are not degraded by digestive enzymes of the small intestine to reach the large intestine to promote the growth of lactic acid bacteria inhabit the large intestine.
    [4] Such lactic acid bacteria growth factors include 4-O-galactopyranosyl-N-acetyl-D-glucosamine, amino sugar, natural oligosaccharide, and inulin type. Fructooligosaccharide [Hu Kyung Taek, Oligosaccharide, Yuhan Culture Co., (1992)], Glycoprotein of potato [Shin Hyun-kyung, Searching for new materials to improve intestinal flora, Food Science and Industry, 25, 83 (1994)], Hemp Additives [Korean Patent Publication] No. 1998-031143].
    [5] According to the results of previous studies by the researchers, a novel fructose polymer called levan derived from microorganisms was produced with high purity of 99% or higher (Korean Patent Publication Nos. 176410 and 145946).
    [6] General characteristics of the fructose polymer Levan are as follows. Fructose polymers are known as levan and inulin, and they are composed differently in the method of binding fructose residues. Inulin is a storage carbohydrate consisting of β-2,1 bonds and having a relatively small molecular weight of 20 to 60 in the degree of polymerization (DP). It is contained in a large amount of pork potatoes, chicory, and dahlia. In contrast, Levan is a water-soluble fructose polymer represented by Glu- (Fru) n, where Glu represents a glucose residue, Fru represents a fructose residue, and n represents a number of about 10 5 . It is made from sugar by the fructose transfer reaction of levanschkrase. Levan's physical properties are amorphous with a wide variety of solubility in cold water, much better than inulin, which hardly dissolves at room temperature (<0.5%). Levan is similar in physical and chemical properties to dextran, so it can be used in place of dextran, such as separation of proteins using plasma substitutes or the formation of aqueous phase separation system of polyethylene glycol / levan [Korean Patent Application No. 1997-74490]. It can be applied to a wide range of fields such as stabilizers, encapsulation reagents [Lwibovici et al., Anticancer Res ., 5, 553 (1985); And Stark et al., Br. J. Exp. Path ., 67, 141 (1986). Recently, Levan has been applied in industrial polymers, food (Hatcher et al., Boprocess , technol ., 11, 1 (1989)), cosmetics and pharmaceuticals [Whiting et al., J. Inst. Brew., 73, 422 (1961); Han, Bioprocess Technol. , 12, 1 (1990).
    [7] A number of methods of preparing levans using levanschkrase have been reported. For example, US Pat. No. 4,879,228 and International Patent Publication No. 86-4091 disclose leban from sugar using microorganisms that act in metabolic processes. In the present invention, the present inventors have proposed a recombinant Levansch mass-produced in E. coli transformed using the Levanschkrase gene of Zymomonas mobilis and Pseudomonas aurantiaca S-4380. Levan was produced using craze [Belghith, H. et al., Biotechnol. Letts, 18, 467 (1996); Korean Patent Publication Nos. 176410 and 145946; And Korean Patent Application No. 2001-41532.
    [8] Enteric Lactobacillus affects a variety of diseases and metabolism, including colorectal cancer, cholesterol content in the body, mineral absorption from the intestine to blood, and constipation. Studies on intestinal microflora caused by levan oligosaccharides are very incomplete, except in animal experiments using levanheptaose (DP = 7) in the diet of Bifidobacteria more than 10-fold increase It was reported that it was reported only [recipitation light, J. Korean. Soc. Food. Sci. Nutr. 29, 35 (2000)], studies on the growth of lactic acid bacteria by Levan are still incomplete.
    [9] Therefore, the present inventors have made intensive research efforts to develop the growth promoting factors of entero lactic acid bacteria, when the diet consisting of the natural polysaccharides levane alone or with lactic acid bacteria, the production of lactic acid in the intestine increases, the pH is lowered and enteric lactic acid bacteria The present invention was completed by confirming the fact that the number increased significantly and confirming the lactic acid bacteria growth promoting effect using Levan.
    [10] Accordingly, an object of the present invention is to provide an entero lactic acid bacteria growth promoting composition comprising a levane.
    [11] In addition, the present invention has an object to provide a pharmaceutical and health food comprising the composition.
    [12] The present invention is characterized by enteric lactic acid bacteria growth promoting composition comprising levan alone or together with lactic acid bacteria.
    [13] In addition, the pharmaceutical and health food containing the composition is another feature.
    [14] The present invention will be described in more detail as follows.
    [15] Levan is a stable biopolymer produced by various food microorganisms including intestinal lactic acid bacteria and efficiently reaches the large intestine and is used as an energy source by the intestinal microorganisms. Levan produces only fructose and a very small amount of glucose upon complete degradation by acid hydrolysis or heat treatment, so there are few anticipated side effects in animals ingested with Levan. In addition, when administered in combination with lactic acid bacteria can improve the acid resistance of the lactic acid bacteria and act as a nutrient source to improve the survival rate of the strain.
    [16] Furthermore, Levan is partially decomposed in the small intestine of the animal and used as a calorie source, but since a large amount of Levan reaches the intestine and is fermented by the intestinal lactic acid bacteria, it can be expected to reduce the amount of calories absorbed when ingesting the same weight as the oligosaccharide orally. have.
    [17] Levan, a fructose polymer used in the present invention, may be used in solid or liquid form. It is preferable to contain 0.1 to 10% by weight of the levan according to the solid content, and 0.1 to 7% by weight of the levan according to the liquid phase. In this case, in the case of solids, when the Levan is less than 0.1% by weight, there is a problem that the effect is low, and when it exceeds 10% by weight, any anxiety often caused by ingestion of non-digestible carbohydrates, for example, light stools, diarrhea, There is possibility of intestinal cramps. However, this problem has not been observed, but only refers to the side effects of other dietary fiber that is common due to the intake of excessively high concentrations of non-digestible carbohydrates. In addition, in the case of liquid phase, if the concentration of the levane is less than 0.1% by weight, there is a problem in that the occurrence of the effect is low, and when it exceeds 7% by weight, the water content is relatively low when mixing the water and the levane becomes difficult to mix. It may contain other conventional dietary components and purified lactic acid bacteria, purified lactic acid bacteria include Streptococcus sp., Pediococcus sp., Peiococcus sp., Leuconostoc sp. ), Lactobicillus sp., Bifidobacterium sp., Etc., and the forms of these lactic acid bacteria include powder, mesh, pellet, and liquid forms. It can be used by processing into a product of, or by adding and mixing directly to a diet. The liquid levane is completely mixed with commercially available microorganisms (dried lactic acid bacteria) in a simple physical manner, in which case no precipitation of levane has been identified. In addition, the mixing ratio (weight ratio) of the dried lactic acid bacteria and levane is 1: 2 to 1:10, preferably 1: 5. If the mixing ratio is less than 1: 2, there is a problem that the intake of Levan is reduced, and when the ratio is greater than 1: 10, there is a problem in that the efficacy of adding lactic acid bacteria is lowered.
    [18] On the other hand, levan oligosaccharide is a substance synthesized by heat treatment, acid hydrolysis, or enzymatic method of levan, and its chemical structure is the same as that of levan, but it is a reduced oligosaccharide, which is selectively used in the large intestine. Suitable.
    [19] The composition prepared as described above has the effect of increasing the number of lactic acid bacteria in the intestine, promoting acid production of acetic acid and lactic acid by fermentation of lactic acid bacteria and acidifying the intestinal pH. In addition, the proliferation effect of the lactic acid bacteria is confirmed even when using Levan alone, the mixed use of the Levan and lactic acid bacteria has the effect of further increasing the proliferation effect of the lactic acid bacteria. In addition, when the liquid Levan / lactic acid bacteria mixture is ingested with the diet, the temporary acidity of the gastric juice by the diet is reduced, thereby suppressing the acid hydrolysis of the Levan and the survival rate of the lactic acid bacteria.
    [20] Levan as an enteric lactic acid bacterium growth promoting agent according to the present invention can be usefully used in various health foods and medicines, etc. The method of manufacturing a drug or health food follows a known method.
    [21] When manufacturing as a pharmaceutical, in addition to the levane or levane / lactic acid bacteria mixture, it can also be mixed into a pharmaceutically acceptable carrier, excipient (forming agent), diluent (diluent), etc. can also be prepared as a powder, granules, capsules or liquids. . In addition, the levan according to the present invention is not particularly limited in its dosage, and may vary according to body absorption, weight, age, sex, health diet, administration time, administration method, excretion rate, and severity of disease. have. Levan is preferably administered at about 0.1 to 10 mg / kg body weight, but higher weight percent mixtures of levan, levan oligosaccharides are also suitable according to the invention. Therefore, the composition containing the active ingredient of the present invention is to be prepared in consideration of the effective amount range, and the unit dosage form formulated in this way according to the judgment of the expert and the needs of the individual to monitor or observe the administration of the drug as needed Specialized medications can be used or administered at regular intervals.
    [22] On the other hand, when manufactured as a health food can be prepared from food materials such as beverages, confectionery.
    [23] Hereinafter, the present invention will be described in more detail based on the following examples, but the present invention is not limited thereto.
    [24] Reference Example
    [25] (1) sample
    [26] Levan was prepared in our laboratory using Zymomonas mobilis and Pseudomonas aurantiaca S-4380. Lactobacillus administered orally with liquid Levan in animal experiments was 1: 1: 2 by weight ratio of Lactobacillus acidophilus , Bifidobacterium longum , and Streptococcus faecium . In the mixed form, the number of lactic acid bacteria administered per day on the basis of viable cell count was 1.3 × 10 8 .
    [27] (2) Leban quantitative method
    [28] The Levan solution was filtered through a 0.45 m filtration membrane, and 20 μl of the filtrate was injected into HPLC (System Gold) [Beckman Co., Ltd.] to quantify the Levan content. HPLC analysis conditions were maintained by distilled water at a rate of 0.4 ml / min using a column (Ionpak KS-802) [Shodex] kept at 50 ℃, it was detected by the refractive index (refractive index).
    [29] (3) lactic acid and pH measurement
    [30] The intestinal contents of rats were centrifuged to recover the liquid components under appropriate conditions, and then 20 μl of the rats were injected into HPLC [Young-In Science, Inc.] to analyze the amount of lactic acid and acetic acid. HPLC analysis was performed by flowing 5 mN aqueous sulfuric acid solution into a column (PRP-X300, 250 x 4.1 mm, 7 m) [Alltech] at a rate of 1 ml / min, measured at 204 nm using a UV detector. It was. The pH measurement was measured using a pH meter (pH-meter 220) [Corning Company].
    [31] (4) Enteric Lactobacillus Assay
    [32] Intestinal contents of rats were subjected to the Mitsuoka method under anaerobic conditions [Jap. J. Microbiol. 13, 383 (1969)] and the intestinal microorganisms were isolated and then cultured in lactic acid bacteria selection medium. The composition of the two types of selective medium used in the experiment is as follows. 1 L of solid selective medium A contains 1% by weight of peptone, 1% by weight of lactose, 1% by weight of yeast extract, 2.5% by weight of sodium acetate, 0.02% by weight of L-cystine, 0.1% by weight of ascorbic acid, 0.5% by weight of precipitated calcium carbonate , 2% by weight of agar, 0.006% by weight of brom creepsole, and 91.874% by weight of water. 1 L of solid selective medium B consisted of 1% by weight of peptone, 1% by weight of yeast extract, 1% by weight of glucose, 1% by weight of precipitated calcium carbonate, 2% by weight of agar, 93.994% by weight of water, and 0.006% by weight of brom crepersol. .
    [33] Example 1 Changes of Intestinal pH, Lactic Acid Production, and Lactic Acid Bacteria in Response to Solid Formation of Zimomonas mobilis-derived Levan
    [34] Seven week-old rats were used and the diet was fed for three weeks, replacing the ingested sample with the Leban diet shown in Table 1 after adapting to a general diet. Experiments were carried out on a total of 20 mice, 10 of each group.
    [35] Dietary Composition (g / kg)ControlLebanese Casein360360 Corn oil7070 cellulose7070 Sucrose430360 Levan070 Choline bitrate66 Mixed minerals5050 Mixed vitamins1414
    [36] Body weights of the control and Levan groups were 235 g in both groups. After diluting the rat stool with 0.1 M phosphate buffer (pH 7.0), the bacteria were inoculated with 0.1 ㎖ in solid selective medium A, incubated anaerobicly for 4 days at 37 ° C, and the number of colonies was counted. . The number of microorganisms is expressed in units of colony forming unit (CFU) / ml. As shown in Table 2, the numbers of entero lactic acid bacteria were 3 × 10 7 and 9 × 10 8 CFU / ml in rats grown in the Levan group and the control group, respectively. It was confirmed that it has a lactic acid bacterium promoting effect.
    [37] divisionControlLebanese Lactobacillus3.0 × 10 7 9.0 × 10 8Total microbial count3.4 × 10 9 1.7 × 10 10Unit: total amount of CFU / feces
    [38] As shown in Table 3, the pH of intestinal contents was 6.9, 7.1, and 6.6 in the small intestine, cecum, and large intestine in the control group, and 6.7 in the Leban group, respectively. , 5.4, 5.0. Therefore, in the Levan group, the cecal contents and colon contents were acidified as compared to the control group.
    [39] divisionControlLebanese PH of small intestine contents6.96.7 PH of the cecal contents7.15.4 PH of colon contents6.65.0
    [40] The amount of lactic acid and acetic acid contained in the intestinal contents was qualitatively and quantitatively analyzed by liquid chromatography. As a result, as shown in Table 4, the concentration ratios of lactic acid / acetic acid in the cecum in the control group and the Leban group were 0.19 and 0.56, respectively. The major organic acids produced in the carbohydrate fermentation of lactic acid bacteria are acetic acid and lactic acid, especially the concentration ratio of lactic acid / acetic acid is an indicator of intestinal flora. That is, the high lactic acid / acetic acid ratio indicates that lactic acid bacteria are present as the dominant flora in the intestine. In addition, acetic acid and lactic acid are low molecular weight organic acids produced during the fermentation process of microorganisms using diets added to the diet, which affects the balance of the intestinal microflora. That is, some are absorbed and metabolized in the body, and the non-absorbed organic acid changes the pH of the intestine to an acidic environment, providing an environment in which harmful microorganisms are unlikely to grow, thereby increasing the number of beneficial microorganisms in the intestine.
    [41] divisionControlLebanese Lactate / acetic acid concentration ratio in the cecum0.190.56 Lactate / Acetic Acid Concentration Ratio in the Large Intestine0.400.92
    [42] Example 2 Change of Intestinal pH with Administration of Pseudomonas neutiaca-derived Levan
    [43] Experiments were performed by substituting Pledomonas neutiaca-derived Levan for Pseudomonas neutiaca under the same experimental conditions as that in Example 1, that is, rats of the same age, same culture conditions, and the same experimental conditions. As shown in Table 5, the pH of intestinal contents was 6.9, 7.1, and 6.6 in the small intestine, caecum, and large intestine, respectively, and 6.8, 5.0, and 5.0 in the Leban diet group. . Therefore, the intestinal lactic acid bacteria growth promoting effect of Levan confirmed in the present invention was not limited to the specific microorganism-derived Levan, but was confirmed as a general characteristic of Levan. That is, Levan is expected to have such an intestinal lactic acid bacterium promoting effect in the Levan produced from the Levanschkrase derived from many other microorganisms in addition to the Simmonosa mobilis, Pseudomonas neutiaca species used by the present inventors.
    [44] divisionControlLebanese PH of small intestine contents6.96.7 PH of the cecal contents7.15.4 PH of colon contents6.65.0
    [45] Example 3: Changes of Intestinal Lactobacillus in Feces of Rats Following Oral Administration of Levan and Lactic Acid Bacteria Mixture
    [46] Seven-week-old rats were used, and freely supplied with normal solids and water, 3 ml of liquid lactobacillus / levane mixtures of different concentrations were administered twice daily. The administration period was 3 weeks, and the control group was orally administered with the same amount of water instead of the mixture. The rats were divided into seven groups and orally administered water, levane 6 wt%, lactic acid bacteria 2 wt%, lactic acid bacteria 2 wt% and 3, 4, 5, 6 wt% mixed solution of levan, respectively, The number was measured and shown in Table 6 below.
    [47] As a result, the increase in the intestinal lactic acid bacteria was increased as the Leban concentration in the mixture increased compared to the control. The two selective media showed similar results, and the highest level of leban concentration (6% by weight) and Lactobacillus mixed solution group showed the best effect. An increase is expected. In addition, the intestinal lactic acid bacteria were also increased compared to the control group when only Levan was administered. Therefore, in order to administer a high concentration of levane, it is possible to increase the enteric lactic acid bacteria flora by using a powder form or pellets in which levane and lactic acid bacteria are mixed.
    [48] divisionSolid Media ASolid Media B water2.2 × 10 8 3.3 × 10 8Levan 6 wt%1.5 × 10 9 1.2 × 10 9Lactobacillus 2% by weight8.4 × 10 8 4.7 × 10 8Lactic acid bacteria 2% by weight + Levan 3% by weight2.5 × 10 9 1.4 × 10 9Lactic acid bacteria 2% by weight + Levan 4% by weight3.5 × 10 9 1.5 × 10 92% by weight of lactic acid bacteria + 5% by weight of Levan4.8 × 10 9 1.4 × 10 9Lactic acid bacteria 2% by weight + Levan 6% by weight4.9 × 10 9 3.4 × 10 9Unit: microbial count (total amount of CFU / feces)
    [49] Example 4 Preparation of Tablet
    [50] Levan 75.75 g
    [51] Lactobacillus 15.15 g
    [52] Corn Starch 7.60g
    [53] 1.00g of silicon dioxide
    [54] 0.50 g of magnesium stearate
    [55] Total amount 100 g
    [56] The tablets were prepared by direct tableting method after mixing the ingredients listed above finely. The total amount of each tablet is 300 mg.
    [57] Example 5: Preparation of Powder
    [58] The same ingredients as listed in Example 4 were used, and powders were prepared by crushing and mixing the ingredients listed above, and 250 mg of the powder was put into a hard capsule to prepare a capsule.
    [59] Example 6
    [60] Lebango H. cultivar with a Leban concentration of 10% by weight (based on solids) in 7-week-old rats (consistent with the composition of the Levan group in Table 1 above, only increased the concentration of Levan to 10% by weight and the concentration of sucrose to 33% by weight). After 21 days of feeding, no obvious side effects such as diarrhea and bleeding were observed. In addition, the solid levane has a final moisture content of less than 3%, when stored in a sealed state, there is no possibility of other bacteria can grow.
    [61] Example 7: Beverage Product Preparation
    [62] Zymomonas mobilis derived Leban 2.5g, lactic acid bacteria 0.5g, glucose 1.25g, maltose 2.5g and 0.5g aromatic substance is diluted in water to prepare a beverage in a conventional manner, but adjusted to 100ml in total for 15 seconds at 100 ℃ Sterilization and cooling to prepare a drink type beverage product.
    [63] As described above, the intestinal lactic acid bacteria number of the animal is dramatically increased when ingesting Levan alone or in combination with lactic acid bacteria, it has the effect of promoting the production of lactic acid and significantly lower the intestinal pH. In addition, the use of the microorganism-derived Levan prevents the lactic acid bacteria having weak acid resistance from being killed in the stomach, thereby providing an effect of reaching a large number of lactic acid bacteria in the intestine. Levan as an intestinal lactic acid bacteria growth promoting agent can be usefully used for various health foods and medicines.
    权利要求:
    Claims (7)
    [1" claim-type="Currently amended] Enteric lactic acid bacteria growth promoting composition, characterized in that it comprises with Levan alone or lactic acid bacteria.
    [2" claim-type="Currently amended] The intestinal lactic acid bacteria growth promoting composition according to claim 1, wherein the mixing ratio of the lactic acid bacteria and levane is 1: 2-1: 10 (weight ratio).
    [3" claim-type="Currently amended] The intestinal lactic acid bacteria growth promoting composition according to claim 1, wherein the levan comprises 0.1 to 10 wt% based on solids.
    [4" claim-type="Currently amended] The intestinal lactic acid bacteria growth promoting composition according to claim 1, wherein the levan comprises 0.1 to 7% by weight on a liquid basis.
    [5" claim-type="Currently amended] The intestinal lactic acid bacteria growth promoting composition according to claim 1, wherein the levane comprises levanoligosaccharide.
    [6" claim-type="Currently amended] Enteric lactic acid bacteria growth promoting agent comprising the composition of claim 1.
    [7" claim-type="Currently amended] Health food comprising the composition of claim 1.
    类似技术:
    公开号 | 公开日 | 专利标题
    JP6416308B2|2018-10-31|Use of purified 2&#39;-fucosyl lactose, 3-fucosyl lactose, and lactodifucotetraose as prebiotics
    AU2017200343B2|2018-11-22|Prebiotic formulations and methods of use
    US20170000811A1|2017-01-05|Prebiotic oligosaccharides
    US20180207165A1|2018-07-26|Methods and compositions for stimulating beneficial bacteria in the gastrointestinal tract
    US9549984B2|2017-01-24|Probiotic oral dosage forms and method of enhancing the stability, thereof
    EP2776048B1|2019-09-18|Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes
    ES2719837T3|2019-07-16|Compositions comprising a bacterial strain of Blautia hydrogenotrophica for use in the treatment of bacterial infections of the gastrointestinal tract
    EP2672980B1|2017-12-06|Synbiotic compositions for restoration and reconstitution of gut microbiota
    US9855288B2|2018-01-02|Processing of natural polysaccharides by selected non-pathogenic microorganisms and methods of making and using the same
    Costalos et al.2003|Enteral feeding of premature infants with Saccharomyces boulardii
    EP2211879B1|2014-05-07|Probiotic compositions and methods for inducing and supporting weight loss
    AU2004254110B2|2007-01-04|Novel galactooligosaccharide composition and the preparation thereof
    Fooks et al.1999|Prebiotics, probiotics and human gut microbiology
    RU2536939C2|2014-12-27|Compositions containing probiotic and prebiotic ingredients and inorganic salts with lactoferrin
    US7846711B2|2010-12-07|Lactobacillus strains and uses thereof
    US6841181B2|2005-01-11|Encapsulated multifunctional biologically active food component, process for its production and its use
    US7101565B2|2006-09-05|Probiotic/prebiotic composition and delivery method
    CN1229115C|2005-11-30|Nutritional formulation containing prebiotic substances
    EP1680501B1|2012-12-19|Stabilized compositions comprising probiotics
    ES2216611T3|2004-10-16|Preparation containing oligosacarids and probiotics.
    US8257693B2|2012-09-04|Composition for maintaining healthy kidney function
    AU750136B2|2002-07-11|Probiotic lactic acid bacterium to treat bacterial infections associated with SIDS
    EP1398369B1|2006-08-02|Bifidobacterium longum bacteria and preparations containing them
    EP1613180B1|2008-01-23|Synbiotic combination
    KR101054631B1|2011-08-04|equol-producing lactic acid bacteria-containing composition
    同族专利:
    公开号 | 公开日
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    法律状态:
    2002-02-06|Application filed by 주식회사 코리즈, 주식회사 고려한백 인터내셔널, 주식회사 리얼바이오텍
    2002-02-06|Priority to KR1020020006644A
    2003-08-14|Publication of KR20030066902A
    优先权:
    申请号 | 申请日 | 专利标题
    KR1020020006644A|KR20030066902A|2002-02-06|2002-02-06|Composition including levan as growth stimulator for intestinal lactic acid-producing bacteria|
    [返回顶部]